Table 2—

Comparison of the glucose, insulin and C-peptide AUCs in type 2 diabetic and nondiabetic subjects

Glucose AUC (mmo/l × h−1) (−15 to 240 min)Insulin AUC* (mU/l × h−1) (−15 to 30 min)Insulin AUC* (mU/l × h−1) (120 to 240 min)Insulin AUC* (mU/l × h−1) (−15 to 240 min)C-peptide AUC (pmol/1/× h−1) (−15 to 240 min)
Type 2 diabetic subjects
 Placebo34.0 (28.0–41.4)13.0 (8.5–19.9)58.1 (41.3–82.0)158.5 (113.3–221.7)6.2 (5.3–7.4)
 Repaglinide27.6 (22.7–33.5)17.8 (11.7–27.2)91.2 (64.7–128.5)244.4 (174.8–341.9)9.1 (7.7–10.8)
 Glipizide27.0 (22.2–32.8)19.2 (12.6–29.3)88.4 (62.7–124.6)233.9 (167.3–327.1)8.7 (7.4–10.3)
 Glibenclamide27.8 (22.9–33.9)14.0 (9.2–21.4)112.2 (79.6–158.1)254.5 (182.0–355.9)8.9 (7.5–10.5)
Nondiabetic subjects
 Placebo21.3 (20.1–22.6)16.8 (12.7–22.3)31.4 (24.1–41.0)137.3 (110.6–170.3)5.9 (5.0–7.0)
 Repaglinide15.7 (14.8–16.6)27.2 (20.5–36.0)52.4 (40.3–68.6)236.5 (190.6–293.4)8.8 (7.4–10.3)
 Glipizide16.6 (15.6–17.6)22.5 (17.0–29.8)62.3 (47.8–81.3)247.4 (199.4–307.0)8.4 (7.1–9.9)
 Glibenclamide17.5 (16.5–18.6)17.3 (13.1–22.9)76.2 (58.4–99.5)238.6 (192.2–296.0)8.5 (7.3–10.0)
  • Data are mean (95% CI).

  • *

    * ANOVA significance level at P <0.02 across both nondiabetic and type 2 diabetic groups;

  • significant difference against placebo (P <0.02);

  • significant difference against glibenclamide (P < 0.02).